{"product_id":"veracyte-business-model-canvas","title":"Veracyte Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte Business Model Canvas: Scaling Precision Diagnostics \u0026amp; Genomics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Veracyte’s business model—this concise Business Model Canvas maps value propositions, key partners, revenue streams, and growth levers to reveal how the company scales in precision diagnostics and genomics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharmaceutical Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte partners with global pharma firms to embed its genomic tests in clinical trials and R\u0026amp;D, helping select patient cohorts for targeted therapies; by end-2025 these collaborations supported \u0026gt;120 oncology trials and generated ~$45M in partner-funded revenue in 2025. These alliances made Veracyte’s platforms a core enabler of precision medicine across multiple cancer indications, cutting trial enrollment time by an average 30%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with academic and clinical research centers—including partnerships supporting Veracyte’s 2024 multicenter Afirma validation study that enrolled \u0026gt;1,200 patients—drive peer-reviewed clinical validation and publication, supplying high-quality samples and specialist input to refine diagnostic algorithms. This academic backing raised diagnostic confidence, contributing to a 12% increase in test utilization in 2024 and strengthening product credibility among clinicians.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte partners with specialized distributors to sell IVD kits and services outside the US, using local expertise to handle regional regs and logistics; in 2024 international revenue reached $122.4M (31% of total), driven by Decipher and Prosigna rollouts across Europe and Asia. This decentralized network cut time-to-market by ~30% for new territories in 2023, enabling scalable growth without heavy fixed overseas infrastructure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Insurance and Managed Care Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte secures formal agreements with private and public payers to ensure reimbursement and wider patient access, showing tests cut unnecessary procedures—e.g., Medicare and major private plans now cover Afirma and Percepta, reducing diagnostic surgeries by ~30% in peer studies.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 expanded coverage policies lowered out‑of‑pocket costs, with payer reimbursement growth driving a ~22% revenue increase year‑over‑year for genomic testing services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormal payer agreements = reimbursement + access\u003c\/li\u003e\n\u003cli\u003eEvidence: ~30% fewer unnecessary procedures\u003c\/li\u003e\n\u003cli\u003eLate‑2025: expanded coverage cut patient costs\u003c\/li\u003e\n\u003cli\u003eResult: ~22% YoY revenue rise for tests\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory and Pathology Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with large commercial laboratories and pathology practices integrate Veracyte tests into standard workflows, cutting sample turnaround to ~3–5 days and helping drive a 2024 volume increase of ~28% in genomic assays year-over-year.\u003c\/p\u003e\n\u003cp\u003eEmbedding Veracyte tech into existing lab infrastructure reduces processing costs per test and raised lab-contracted revenue to an estimated $85–95M in 2024, boosting market penetration and clinician ordering ease.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster turnaround: ~3–5 days\u003c\/li\u003e\n\u003cli\u003e2024 assay volume +28% YoY\u003c\/li\u003e\n\u003cli\u003e2024 lab-contracted revenue ~$85–95M\u003c\/li\u003e\n\u003cli\u003eImproved clinician adoption and reporting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte partnerships drive faster trials, +30% enrollment cuts and 3–5 day TAT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte’s key partnerships—pharma trials (\u0026gt;120 trials, ~$45M partner revenue in 2025), academic centers (1,200+ patients in 2024 Afirma study), distributors (2024 international revenue $122.4M, 31% of total), payers (coverage driving ~22% YoY test revenue growth), and lab partners (2024 assay volume +28%, lab-contracted revenue $85–95M)—cut enrollment and turnaround times ~30% and 3–5 days respectively.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003eTrials \/ revenue\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;120 \/ ~$45M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\u003c\/td\u003e\n\u003ctd\u003eStudy size\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,200 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl distributors\u003c\/td\u003e\n\u003ctd\u003eIntl revenue\u003c\/td\u003e\n\u003ctd\u003e$122.4M (31%) (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eRevenue growth\u003c\/td\u003e\n\u003ctd\u003e+22% YoY (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs\u003c\/td\u003e\n\u003ctd\u003eAssay vol \/ revenue\u003c\/td\u003e\n\u003ctd\u003e+28% \/ $85–95M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Veracyte detailing customer segments, channels, value propositions, key activities, resources, partnerships, cost structure, and revenue streams, reflecting real-world operations and strategic plans to support presentations and investor discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Veracyte’s business model with editable cells to quickly identify diagnostic revenue streams, payer relationships, and commercialization levers—perfect for boardrooms, team collaboration, or rapid competitor comparison.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenomic Research and Test Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte focuses on discovery and development of RNA-based genomic signatures, using ML and bioinformatics to identify markers that separate benign from malignant lesions; as of Q4 2025 the company reported 25 peer-reviewed validations and a 30% reduction in unnecessary surgeries in thyroid nodules versus standard care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Validation and Regulatory Submission\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte spends tens of millions annually on large-scale clinical studies—$45M+ in 2024 R\u0026amp;D—to validate test sensitivity\/specificity (eg, Afirma GSC showing \u0026gt;94% negative predictive value in published cohorts) and secure FDA and global approvals; this rigorous validation underpins reliable, actionable results that drive physician adoption and reimbursement decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Complexity Laboratory Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte runs centralized CLIA-certified, CAP-accredited labs that handle full workflows—sample receipt, RNA extraction, sequencing, and report generation—processing ~150k samples in 2024 and supporting $287M revenue; tight QC (6-sigma processes, 24–48h median TAT) ensures consistent, timely results for clinicians.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Clinical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA specialized sales force of ~200 reps (2025) engages physicians, pathologists, and hospital admins to sell Veracyte’s genomic tests, driving $328M revenue in 2024 and 22% YoY growth; clinical-education programs train clinicians to interpret complex genomic data and increase test adoption and reimbursement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: physicians, pathologists, hospital admins\u003c\/li\u003e\n\u003cli\u003eSales reps: ~200 (2025)\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $328M; growth: 22% YoY\u003c\/li\u003e\n\u003cli\u003eGoal: shift standard of care to data-driven diagnostics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Analytics and Bioinformatic Scaling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging and analyzing the genomic data from Veracyte’s platforms—over 120,000 de-identified test results in 2024—remains a core operational pillar, with cloud pipelines processing terabytes monthly to keep turnaround times under 7 days.\u003c\/p\u003e\n\u003cp\u003eVeracyte updates proprietary databases and algorithms continuously; R\u0026amp;D spend was $88.5M in 2024 to boost test AUCs (area under curve) and support new diagnostics under development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120,000+ de-identified tests (2024)\u003c\/li\u003e\n\u003cli\u003eTerabytes processed monthly; \u0026lt;7-day TAT\u003c\/li\u003e\n\u003cli\u003e$88.5M R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eOngoing AUC improvements and pipeline for new tests\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: $328M revenue, 150k RNA samples, 22% growth and Afirma GSC NPV\u0026gt;94%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte develops RNA-based genomic tests, running CLIA\/CAP labs that processed ~150k samples in 2024, while spending $88.5M R\u0026amp;D and $45M on large clinical studies to validate tests (Afirma GSC NPV \u0026gt;94%), driving $328M revenue (2024) and 22% YoY growth via a ~200-rep salesforce.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSamples processed\u003c\/td\u003e\n\u003ctd\u003e~150,000 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$88.5M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical study spend\u003c\/td\u003e\n\u003ctd\u003e$45M+ (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$328M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY growth\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps\u003c\/td\u003e\n\u003ctd\u003e~200 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma GSC NPV\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;94% (published cohorts)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you’re previewing is the exact Veracyte Business Model Canvas you’ll receive after purchase—not a mockup or sample—and when you complete your order you’ll get this same fully formatted, ready-to-edit file in Word and Excel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748830327161,"sku":"veracyte-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/veracyte-business-model-canvas.png?v=1772211464","url":"https:\/\/growthsharematrix.com\/products\/veracyte-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}